The market has climbed 3.4% in the last 7 days and is up 30% over the last 12 months, with earnings expected to grow by 16% per annum over the next few years. In such a robust environment, reliable ...

Pfizer's revenue, earnings, and stock price dropped off a cliff due to its inability to sustain the incredible sales ...

Dividend investors looking to maximize income will appreciate this trio of industry leaders.

The company is conservative by nature and has one of the best balance sheets in the space, with leverage of just 3.3 times.

April 2026 Top 25 high-yield dividend stock watchlist: quality/value picks, 3.86% yield, 19% CAGR, ~34% undervaluation—see ...

Rithm Capital Corp. is rated a Buy due to C-Corp conversion, asset management growth, and current valuation. Learn more about ...

The Schwab US Dividend Equity ETF (NYSEARCA:SCHD) has been an excellent holding in the past few months, and it has undone ...

However, there are some outliers. One of those is Ares Capital Corporation (NASDAQ: ARCC). The business development company ...

Scotiabank stock is a fair buy here for income and long-term growth. The post A 4.5% Dividend Yield: I’m Buying This TSX ...

FS KKR Capital Corp (FSK) cut its quarterly distribution from $0.70 to $0.48, signaling structural earnings pressure. FS KKR Capital’s 63% floating-rate portfolio yields fell 70 basis points in one ...

Oil rises, cash gushes—and shareholders get paid. Strong payouts ride the upcycle, but as capex rises, the real question is: ...

Pharmaceutical companies AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, ...